34 Investor presentation Full year 2024 siRNA platform expected to deliv areas in alignment with corporat Progress with the siRNA platform Distribution of siRN 12 phase 1 trial initiations with GalXC TM since 2017 Rivfloza TM the first Novo Nordisk siRNA drug, approved in 2023 3 phase 1 trial initiations with GalXC-Plus TM More than 50% of upcoming phase 1 trials expected to be with GalXC-Plus TM Diabetes and Obes CVD and MASH CVD: Cardiovascular disease; MASH: Metabolic dysfunction-associated steatohepatitis; RBD: Rare blood disorders; RED: Rare endocr Note: A project is defined when a target is identified and assigned team ask for resources to evaluate proof of concept
Download PDF file